📊 BCAB Key Takeaways
Is BioAtla, Inc. (BCAB) a Good Investment?
BioAtla is a pre-revenue biotech company in critical financial distress with negative stockholders' equity of -$36.2M and liabilities exceeding total assets by 3.6x. With only $7.1M in cash and negative operating cash flow of $48.2M annually, the company has approximately 1.7 months of runway and faces imminent insolvency without significant capital infusion or immediate revenue generation.
BioAtla's fundamentals are very weak: it remains pre-revenue, deeply loss-making, and is operating with negative equity and sub-1.0 liquidity ratios. While net loss and diluted EPS improved year over year, the balance sheet and cash burn profile suggest financing dependence remains the dominant fundamental driver until the company demonstrates durable revenue generation or a materially longer cash runway.
Why Buy BioAtla, Inc. Stock? BCAB Key Strengths
- YoY net income improving 14.6%, indicating management efforts to reduce burn rate
- EPS loss narrowing 29.9% YoY shows operational efficiency gains in pre-revenue phase
- Retained $7.1M in cash reserves despite ongoing losses and negative equity position
- Net loss improved 43.5% year over year, indicating some reduction in earnings pressure
- Diluted EPS improved 44.2% year over year, showing lower per-share loss versus the prior period
- No long-term debt is disclosed, so financial stress appears driven more by operating losses than debt servicing
BCAB Stock Risks: BioAtla, Inc. Investment Risks
- Negative stockholders' equity of -$36.2M indicating technical insolvency and balance sheet deterioration
- Zero revenue with liabilities ($50M) nearly 4x total assets ($13.8M), signaling failed commercialization
- Current ratio of 0.37x reflects severe liquidity crisis and inability to meet near-term obligations
- Negative free cash flow of $48.2M annually with minimal runway—existential risk without emergency financing
- Pre-revenue biotech pipeline with uncertain clinical/commercial outcomes and extended R&D timelines
- 7 Form 4 insider filings in 90 days may indicate insider selling or loss of confidence
- The business generated no revenue in the latest period, so growth quality is currently unproven
- Negative stockholders' equity and a 0.54x current ratio indicate a highly strained financial position
- Operating cash outflow of $40.29M against only $8.32M of cash implies significant near-term funding risk
Key Metrics to Watch
- Cash burn rate trajectory and estimated months of runway to insolvency
- New financing announcements or partnership/licensing deals for asset monetization
- Revenue recognition from any clinical trial completions, regulatory approvals, or product launches
- Changes in insider transaction patterns and director/officer holdings
- Quarterly operating cash burn relative to cash and equivalents
- Any sustained revenue generation from collaborations, milestones, or product-related commercialization
BioAtla, Inc. (BCAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCAB Profit Margin, ROE & Profitability Analysis
BCAB vs Healthcare Sector: How BioAtla, Inc. Compares
How BioAtla, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioAtla, Inc. Stock Overvalued? BCAB Valuation Analysis 2026
Based on fundamental analysis, BioAtla, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioAtla, Inc. Balance Sheet: BCAB Debt, Cash & Liquidity
BCAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioAtla, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
BCAB Revenue Growth, EPS Growth & YoY Performance
BCAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$25.8M | $-0.69 |
| Q2 2023 | N/A | -$28.9M | $-0.75 |
| Q1 2023 | N/A | -$24.3M | $-0.58 |
| Q3 2022 | N/A | -$22.9M | $-0.68 |
| Q2 2022 | N/A | -$28.9M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioAtla, Inc. Dividends, Buybacks & Capital Allocation
BCAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioAtla, Inc. (CIK: 0001826892)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCAB
What is the AI rating for BCAB?
BioAtla, Inc. (BCAB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCAB's key strengths?
Claude: YoY net income improving 14.6%, indicating management efforts to reduce burn rate. EPS loss narrowing 29.9% YoY shows operational efficiency gains in pre-revenue phase. ChatGPT: Net loss improved 43.5% year over year, indicating some reduction in earnings pressure. Diluted EPS improved 44.2% year over year, showing lower per-share loss versus the prior period.
What are the risks of investing in BCAB?
Claude: Negative stockholders' equity of -$36.2M indicating technical insolvency and balance sheet deterioration. Zero revenue with liabilities ($50M) nearly 4x total assets ($13.8M), signaling failed commercialization. ChatGPT: The business generated no revenue in the latest period, so growth quality is currently unproven. Negative stockholders' equity and a 0.54x current ratio indicate a highly strained financial position.
What is BCAB's revenue and growth?
BioAtla, Inc. reported revenue of $0.0.
Does BCAB pay dividends?
BioAtla, Inc. does not currently pay dividends.
Where can I find BCAB SEC filings?
Official SEC filings for BioAtla, Inc. (CIK: 0001826892) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCAB's EPS?
BioAtla, Inc. has a diluted EPS of $-1.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BCAB a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, BioAtla, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BCAB stock overvalued or undervalued?
Valuation metrics for BCAB: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BCAB stock in 2026?
Our dual AI analysis gives BioAtla, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCAB's free cash flow?
BioAtla, Inc.'s operating cash flow is $-48.2M, with capital expenditures of N/A.
How does BCAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.37 (avg: 2).